Kedrion S.p.A. Board of Directors approves 2009 financial statements
The Board of Directors of Kedrion SpA – specialising in the development, manufacture and distribution of plasma derived medicinal products, led by Paolo Marcucci, President and CEO – met today to approve the 2009 Financial Statements. In the financial year 2009, Kedrion Group achieved some major results, despite the challenging scenario, retaining its leading position
Growth of the Kedrion Group: expansion of the Hungarian plant starting now. A new Plasmaphereris centre settled in Budapest
Kedrion Group’s growth strategy is progressing in two directions: one is the vertical integration of its operations, the other is the expansion of its production capacity aimed at consolidating its international market share, especially in Europe. The start of the upgrading and expansion of the Gödöllo plant, commissioned to the Engineering Company Foster Wheeler Italiana
Kedrion: AIFA’s incentives to seven investment plans
AIFA, the Italian Medicine Agency, will give the incentives planned under the 2008 framework agreements to seven investment plans submitted by Kedrion, a biopharmaceutical company which is the national leader in the development, manufacture and distribution of plasma derivative medicines. This accolade by AIFA – which has allocated 3,184,025 euros’ worth of resources to investments
Four new departments in the Bolognana site. Investiments in continuous plant and process improvement Keep Flowing
The investments for the continuous improvement of the manufacturing processes and plants of Kedrion are going on at a fast pace. After passing the AIFA inspection (AIFA is the Italian Drugs Agency) and proving to comply with international Good Manufacturing Practices (GMP), the process for the authorisation to operate with four new departments in the
Paolo Marcucci has joined PPTA’s Global Board of Directors
Paolo Marcucci, President and CEO of Kedrion, has joined the Global Board of Directors of the Plasma Protein Therapeutics Association (PPTA). “We are excited that Mr. Marcucci is joining the Global Board of Directors” said Jan M. Bult, PPTA’s President. “Paolo Marcucci understands the many challenges confronting our industry and the patients we serve. He
Production of plasma-derived products to highest international quality standards: Kedrion technology for the new Moscow plant
Kedrion embarks on its second technology transfer to Russia following the one in Kirov, by signing an agreement in Moscow for the development of a plasma-derivatives production plant to the highest international quality, safety and efficiency standards. The agreement signed between Kedrion, the Dutch company BTI and the Moscow Government covers both the engineering operations
Kedrion buys a production plant in Hungary from Teva Pharmaceutical Industries Ltd
Kedrion SpA has bought yesterday from Teva Pharmaceutical Industries Ltd (a leading global pharmaceutical company) 100% of the shares in Human Bioplazma Manufacturing and Trading Ltd, a company established under the Hungarian law and based in Gödöllo (Budapest). Kedrion thus acquires a manpower of 127 employees, a fractionation and production plant with a productive capacity
Kedrion stakes on “vertical integration”, two agreements signed to buy four plasma collection centres in the USA and Germany
Kedrion has recently finalised two important agreements for the purchase of four plasma collection centres, two in the United States (Florida and Alabama) and two in Germany (Bavaria). The agreement to buy the two US centres, Pensacola (Florida) and Mobile (Alabama), has been signed with Life Therapeutics, a leader in plasma collection for therapeutic and
EMAS registration for Kedrion: the company’s environmental policy reinforced
Kedrion SpA, specialized in the production of plasma–derived products, is one of the five Italian pharmaceutical companies which got EMAS registration. The company has joined an “Environmental Programme” and has thereby assumed specific environmental policy commitments. At the same time, it has drawn up an “Environmental Statement” which – in terms of regulation CE 761/2001
New plant in the Kedrion factory: 7 million invested and a 50% increase in production of Factor VIII and Factor IX
The new production department for sterile “Filling and Freeze-Drying of Heat-treated Coagulation Factors” in the Kedrion factory in Bolognana is now in operation. 7 million euros invested and a forecast increase of 50% in the production of Factor VIII and Factor IX which currently represent the 20% of turnover and the asset for the Contract